<DOC>
	<DOCNO>NCT01166139</DOCNO>
	<brief_summary>A phase IIa open-label single center pilot study assess safety efficacy Nilotinib patient Scleroderma .</brief_summary>
	<brief_title>Nilotinib Treatment Systemic Sclerosis</brief_title>
	<detailed_description>The purpose study learn safe tolerable medication call Nilotinib ( Tasigna ) patient diagnose Systemic Sclerosis . Systemic Sclerosis ( scleroderma ) autoimmune disease involve skin , blood vessel , muscle connective tissue , major organ include lung , kidney , gastrointestinal tract , heart . The exact cause disorder know time drug proven cure scleroderma . Experiments do animal model `` test-tube '' model fibrosis suggest Nilotinib may useful therapy scleroderma . Nilotinib medication market FDA approve treatment type leukemia call chronic myelogenous leukemia ( CML ) . It oral medication , take two time day . This 32 week , open-label , Phase IIa , single center clinical trial . The primary goal study assess safety tolerability Nilotinib patient scleroderma . The secondary goal ass effective Nilotinib treat patient scleroderma . The clinical test perform Modified Rodnan Skin Score , Pulmonary Function Tests , Echocardiograms , Electrocardiograms , blood skin collect study help determine whether therapy safe effective , also improve understand scleroderma .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>1 . Age great equal eighteen year . 2 . Clinical diagnosis diffuse systemic sclerosis ACR criterion , stable modify Rodnan skin score one month precede introduction oral nilotinib therapy . The modified Rodnan skin score must great equal sixteen screen initiation therapy . 3 . Disease duration less equal 3 year define date onset first nonRaynaud 's symptom . 4 . Estimated ejection fraction great 50 % echocardiography 1 . Inability render inform consent accordance institutional guideline . 2 . Disease duration great 3 year . 3 . Patients mixed connective tissue disease `` overlap '' ( i.e . satisfy one set ACR criterion rheumatic disease . ) 4 . Limited scleroderma . 5 . Systemic sclerosislike illness associate environmental ingested agent toxic rapeseed oil , vinyl chloride , bleomycin . 6 . Ongoing treatment immunosuppressive therapy include cyclophosphamide , azathioprine , mycophenolic acid , methotrexate , cyclosporine , use medication within 1 month trial entry . 7 . The use antifibrotic agent include colchicine , Dpenicillamine , minocycline , Type 1 oral Collagen month prior enrollment . 8 . Use prior month corticosteroid dose exceed equivalent prednisone 10 mg daily . Use corticosteroid &lt; 10 mg prednisone continue course study . 9 . Concurrent serious medical condition opinion investigator make patient inappropriate study uncontrollable CHF , arrhythmia , severe pulmonary systemic hypertension , severe GI involvement , hepatic impairment , serum creatinine great 2.0 , active infection , severe diabetes , unstable atherosclerotic cardiovascular disease , malignancy , HIV , severe peripheral vascular disease . 10 . History pancreatitis . 11 . Prolonged QTc interval define QTc &gt; 450 msec 12 . Patients require ongoing use medication antiarrhythmic ( include , limited amiodarone , disopyramide , procainamide , quinidine sotalol ) prolong QTc interval ( include , limited chloroquine , halofantrine , clarithromycin , haloperidol , methadone , moxifloxacin , bepridil pimozide ) exclude . 13 . Patients require ongoing use medication potent inhibitor inducer CYP3A4 . 14 . A positive pregnancy test entry study . Men woman reproductive potential require use effective mean contraception course study . 15 . Participation another clinical research study involve evaluation another investigational drug within ninety day entry study . 16 . The presence severe lung disease define diffusion capacity le 30 % predict .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Systemic Sclerosis</keyword>
</DOC>